| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/012003 |
|---|---|---|
| | Serial No. | 09/905,592 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant | Keiya Ozawa et al. |
| | Filing Date | July 13, 2001 |
| | Group | 1636 |
| (37 C.F.R. § 1.98(b)) | IDS Filed | February 19, 2004 |

**U.S. PATENTS**

| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| | | | | | | |

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| | | | | | | |

**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)**

| | |
|---|---|
| Supplemental over IDS 2/23/04 | Anderson, "Human Gene Therapy" *Nature* 392(Supp.):25-30 (1998). |
| | Cheok, "Cancer Fears Cast Doubts on Future of Gene Therapy" *Nature* 421:678 (2003). |
| | Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" *Journal of Hepatology* 39:731-737 (2003). |
| | Juengst, "What Next for Human Gene Therapy" *BMJ* 326:1410-1411 (2003). |
| | Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon-γ through Direct Inhibition of Cell Proliferation and Activation of Antitumour Host Mechanisms," *Immunology* 105:92-100 (2002). |
| | Kmiec "Gene Therapy" *American Scientist* 87:240-247 (1999). |
| | Marcinkowska and Więdlocha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," Acta Biochimica Polonica 49(3):735-745 (2002). |
| | Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," *The Journal of Biological Chemistry*, 269(8):5976-5980 (1994). |
| | O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," *The EMBO Journal* 17(4):1006-1018 (1998). |
| | Verma and Somia, "Gene Therapy-Promises, Problems and Prospects," *Nature* 389:239-242 (1997). |
| | Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent *in Vivo*," *The Journal of Biological Chemistry*, 270(40):23322-23329 (1995). |
| | Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β-1 (TGFβ-1) in Human Neuroendocrine Tumour Cells," *Gut* 52:1308-1316 (2003). |
| | |

| EXAMINER | DATE CONSIDERED |
|---|---|

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/012003 |
|---|---|---|
| | Serial No. | 09/905,592 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant | Keiya Ozawa et al. |
| | Filing Date | July 13, 2001 |
| | Group | 1636 |
| (37 C.F.R. §1.98(b)) | IDS Filed | April 16, 2004 |

U.S. PATENTS

| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| | ~~WO 93/10161~~ | ~~May 27, 1993~~ | ~~WIPO~~ | | | |

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

| | |
|---|---|
| Duplicative over IDS 4/20/04 | Gearing et al., "The IL-6 Signal Transducer, gp130: An Oncostatin M Receptor and Affinity Converter for the LIF Receptor," *Science* 255(5050):1434-1437 (1992). |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| EXAMINER | DATE CONSIDERED |
|---|---|

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

| SUBSTITUTE FORM PTO-1449 (MODIFIED) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/012003 |
|---|---|---|---|
| | | Serial No. | 09/905,592 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant | Keiya Ozawa et al. |
| | | Filing Date | July 13, 2001 |
| | | Group | 1636 |
| (37 C.F.R. § 1.98(b)) | | IDS Filed | May 26, 2004 |

U.S. PATENTS

| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| | | | | | | |

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

| | |
|---|---|
| M | Alexander et al., "Point Mutations within a Dimer Interface Homology Domain of c-Mpl Induce Constitutive Receptor Activity and Tumorigenicity," *The EMBO Journal* 14(22):5569-5578 (1995). |
| | Bazan, "Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily," *Proc. Natl. Acad. Sci. USA* 87:6934-6938 (1990). |
| | Heldin, "Dimerization of Cell Surface Receptors in Signal Transduction," *Cell* 80:213-223 (1995). |
| | Ihle, "Cytokine Receptor Signalling," *Nature* 377:591-594 (1995). |
| | Murakami et al., "Critical Cytoplasmic Region of the Interleukin 6 Signal Transducer gp130 Is Conserved in the Cytokine Receptor Family," *Proc. Natl. Acad. Sci. USA* 88:11349-11353 (1991). |
| | Ozawa et al., US 2002/0004582 A1, published January 10, 2002. |
| | Ozawa et al., US 2003/0166161 A1, published September 04, 2003. |
| | Omura et al., "Acceleration of Granulocyte Colony-Stimulating Factor-Induced Neutrophilic Nuclear Lobulation by Overexpression of Lyn Tyrosine Kinase," *Eur. J. Biochem.* 269:381-389 (2002). |
| M | Thornton, "Evolution of Vertebrate Steroid Receptors from an Ancestral Estrogen Receptor by Ligand Exploitation and Serial Genome Expansions," *Proc. Natl. Acad. Sci. USA* 98(10):5671-5676 (2001). |
| | |
| | |
| | |
| | |
| | |

EXAMINER [signature] DATE CONSIDERED 4/25/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/012003 |
|---|---|---|
| | Serial No. | 09/905,592 |
| | Applicant | Keiya Ozawa et al. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Filing Date | July 13, 2001 |
| | Group | 1655 |
| (37 C.F.R. §1.98(b)) | IDS Filed | September 19, 2002 |

U.S. PATENTS

| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| | | | | | | |

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

| | |
|---|---|
| | Chan et al., "A Murine Cytokine Fusion Toxin Specifically Targeting the Murine Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Receptor on Normal Committed Bone Marrow Progenitor Cells and GM-CSF-Dependent Tumor Cells," *Blood* 86:2732-2740 (1995). |
| | Ito et al., "G-CSFR-Estrogen-R Fusion cDNA as a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Stem Cells," (Abstract 538) *Blood* 88:137A (1996). |
| | Jackson et al., "Hormone-Conditional Transformation by Fusion Proteins of c-Abl and its Transforming Variants," *EMBO J* 12:2809-2819 (1993). |
| | Nagata and Fukunaga, "Granulocyte Colony-Stimulating Factor and its Receptor," *Prog. Growth Factor Res.*, 3:131-141 (1991). |
| | Ozawa et al., "Development of a Novel Selective Amplifier Gene for *In Vivo* Selective Expansion of Transduced Hematopoietic Stem Cells," (Abstract 161) *Experimental Hematology* 24:1053 (1996). |
| | Williams and Park, "Hematopoietic Effects of a Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin-3 Fusion Protein," *Cancer* 67(Supplement):2705-2707 (1991). |

EXAMINER [signature] DATE CONSIDERED 4/20/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/012003 |
|---|---|---|
| | Serial No. | 09/905,592 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant | Keiya Ozawa et al. |
| | Filing Date | July 13, 2001 |
| | Group | 1636 |
| (37 C.F.R. § 1.98(b)) | IDS Filed | February 19, 2004 |

U.S. PATENTS

| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| | | | | | | |

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

| | |
|---|---|
| M | Anderson, "Human Gene Therapy" *Nature* 392(Supp.):25-30 (1998). |
| | Cheok, "Cancer Fears Cast Doubts on Future of Gene Therapy" *Nature* 421:678 (2003). |
| | Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" *Journal of Hepatology* 39:731-737 (2003). |
| | Juengst, "What Next for Human Gene Therapy" *BMJ* 326:1410-1411 (2003). |
| | Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon-γ through Direct Inhibition of Cell Proliferation and Activation of Antitumour Host Mechanisms," *Immunology* 105:92-100 (2002). |
| | Kmiec "Gene Therapy" *American Scientist* 87:240-247 (1999). |
| | Marcinkowska and Więdlocha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," Acta Biochimica Polonica 49(3):735-745 (2002). |
| | Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," *The Journal of Biological Chemistry*, 269(8):5976-5980 (1994). |
| | O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," *The EMBO Journal* 17(4):1006-1018 (1998). |
| | Verma and Somia, "Gene Therapy-Promises, Problems and Prospects," *Nature* 389:239-242 (1997). |
| | Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent *in Vivo*," *The Journal of Biological Chemistry*, 270(40):23322-23329 (1995). |
| M | Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β-1 (TGFβ-1) in Human Neuroendocrine Tumour Cells," *Gut* 52:1308-1316 (2003). |
| | |

| EXAMINER | DATE CONSIDERED 4/25/05 |
|---|---|

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/012003 |
|---|---|---|
| | Serial No. | 09/905,592 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant | Keiya Ozawa et al. |
| | Filing Date | July 13, 2001 |
| | Group | 1636 |
| (37 C.F.R. §1.98(b)) | IDS Filed | April 16, 2004 |

U.S. PATENTS

| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| M | WO 93/10151 | May 27, 1993 | WIPO | | | |

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

| | |
|---|---|
| M | Gearing et al., "The IL-6 Signal Transducer, gp130: An Oncostatin M Receptor and Affinity Converter for the LIF Receptor," *Science* 255(5050):1434-1437 (1992). |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

EXAMINER [signature] DATE CONSIDERED 4/25/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

| SUBSTITUTE FORM PTO-1449 (MODIFIED) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/012003 |
|---|---|---|---|
| | | Serial No. | 09/905,592 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant | Ozawa et al. |
| | | Filing Date | July 13, 2001 |
| | | Group | 1636 |
| (37 C.F.R. § 1.98(b)) | | IDS Filed | February 24, 2005 |

U.S. PATENTS

| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| M | JP 8-504320A | 14 May 1996 | Japan | | | Yes |
| | | | | | | |
| | | | | | | |
| | | | | | | |

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

| | |
|---|---|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| EXAMINER | DATE CONSIDERED 4/25/05 |
|---|---|

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

| SUBSTITUTE FORM PTO-1449 (MODIFIED) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/012003 |
|---|---|---|---|
| | | Serial No. | 09/905,592 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant | Ozawa et al. |
| | | Filing Date | July 13, 2001 |
| | | Group | 1636 |
| (37 C.F.R. § 1.98(b)) | | IDS Filed | October 20, 2004 |

U.S. PATENTS

| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

| | |
|---|---|
| M | Baumann et al., "Signaling by the Cytoplasmic Domain of Hematopoietin Receptors Involves Two Distinguishable Mechanisms in Hepatic Cells," *J Biol Chem.* 269(23):16297-16304 (1994). |
| | Skoda et al., "Murine *c-mpl*: a Member of the Hematopoietic Growth Factor Receptor Superfamily that Transduces a Proliferative Signal," *EMBO J.* 12(7):2645-2653 (1993). |
| h | Vigon et al., "Characterization of the Murine *Mpl* Proto-Oncogene, a Member of the Hematopoietic Cytokine Receptor Family: Molecular Cloning, Chromosomal Location and Evidence for a Function in Cell Growth," *Oncogene* 8(10):2607-2615 (1993). |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

EXAMINER [signature] DATE CONSIDERED 4/20/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.